Literature DB >> 406031

Plasma exchange in the long-term management of Waldenström's macroglobulinemia.

N A Buskard, D A Galton, J M Goldman, E M Kohner, C F Grindle, D L Newman, K W Twinn, R M Lowenthal.   

Abstract

Two patients with Waldenström's macroglobulinemia (WM), which had become resistant to cytotoxic drugs, were treated for features of the hyperviscosity syndrome by repeated plasma exchange with the continuous-flow blood-cell separator over periods of 36 and 28 months, respectively. After four initial weekly plasma exchanges the procedure was carried out every 4 to 6 weeks and both patients tolerated it well. Relative viscosity of the serum was maintained within the normal range in one patient, and both patients remained free of symptoms of the hyperviscosity syndrome. The results suggest that treatment of WM by long-term "maintenance" plasma exchange alone should be considered in any patient with complications due to chemotherapy or whose disease fails to respond to chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 406031      PMCID: PMC1879704     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  12 in total

1.  SERUM PROTEIN DISORDERS CAUSING CLINICAL SYMPTOMS IN MALIGNANT NEOPLASTIC DISEASE.

Authors:  J L FAHEY
Journal:  J Chronic Dis       Date:  1963-07

2.  SERUM HYPERVISCOSITY SYNDROME.

Authors:  J L FAHEY; W F BARTH; A SOLOMON
Journal:  JAMA       Date:  1965-05-10       Impact factor: 56.272

3.  Plasmapheresis therapy in macroglobulinemia.

Authors:  A SOLOMON; J L FAHEY
Journal:  Ann Intern Med       Date:  1963-05       Impact factor: 25.391

4.  The ocular manifestations of Waldenstrom's macroglobulinemia and its treatment.

Authors:  A L ACKERMAN
Journal:  Arch Ophthalmol       Date:  1962-06

5.  Treatment of Waldenstrom's macroglobulinemia by plasmapheresis.

Authors:  P J SCHWAB; J L FAHEY
Journal:  N Engl J Med       Date:  1960-09-22       Impact factor: 91.245

6.  Correction of hypocalcaemic symptoms during plasma exchange.

Authors:  N A Buskard; Z Varghese; M R Wills
Journal:  Lancet       Date:  1976-08-14       Impact factor: 79.321

7.  Letter: Immunoblasts.

Authors:  H H Fudenberg
Journal:  Lancet       Date:  1975-08-23       Impact factor: 79.321

8.  Macroglobulinemia: an analysis for forty patients.

Authors:  M R MacKenzie; H H Fudenberg
Journal:  Blood       Date:  1972-06       Impact factor: 22.113

9.  Method of removing abnormal protein rapidly from patients with malignant paraproteinaemias.

Authors:  R Powles; C Smith; J Kohn; G Hamilton Fairley
Journal:  Br Med J       Date:  1971-09-18

10.  Waldenström's macroglobulinemia: review of 45 cases.

Authors:  M Krajny; W Pruzanski
Journal:  Can Med Assoc J       Date:  1976-05-22       Impact factor: 8.262

View more
  6 in total

1.  Plasma exchange and plasmapheresis.

Authors:  N A Buskard
Journal:  Can Med Assoc J       Date:  1978-10-07       Impact factor: 8.262

Review 2.  Plasmapheresis in paraproteinemia.

Authors:  H H Euler; N Schmitz; H Löffler
Journal:  Blut       Date:  1985-06

3.  Anemia, splenomegaly and hyperviscosity syndrome.

Authors:  W Pruzanski; R Chu; N F Damji; S Galler; C S Norman
Journal:  Can Med Assoc J       Date:  1980-10-18       Impact factor: 8.262

4.  Waldenstrom macroglobulinemia presenting as isolated persistent epistaxis: a very rare presentation.

Authors:  Vinish Agarwal; Saurabh Varshney; S S Bist; Sanjiv Bhagat; Sarita Mishra; Mamta Goyal; Geeta Negi; Namita Kabdiwal
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2012-12-22

5.  Plasma exchange treatment of peripheral neuropathy associated with plasma cell dyscrasia.

Authors:  W H Sherman; M R Olarte; G McKiernan; K Sweeney; N Latov; A P Hays
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-08       Impact factor: 10.154

6.  Retroperitoneal haemorrhage with abscess formation complicating Waldenström's macroglobulinaemia.

Authors:  R Bohus; W C Waltzer; Z Frischer; M Gonder
Journal:  Int Urol Nephrol       Date:  1985       Impact factor: 2.370

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.